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Antibody-based cancer immune therapy has attracted lots of
research interest in recent years; however, it is greatly limited by
the easy distribution and burst release of antibodies. In addition,
after the clearance of the tissue, healthy tissue regeneration is
another challenge for cancer treatment. Herein, we have developed
a specific immunological tissue engineering scaffold using the
agonistic mouse anti-human CD40 antibody (CD40mAb) incorpo-
rated into poly(L-lactide) (PLLA) electrospun fibers through the
dopamine (PDA) motif (PLLA-PDA-CD40mAb). CD40mAb is
successfully incorporated onto the surface of the electrospun
fibrous scaffold, which is proved by immunofluorescence staining,
and the PLLA-PDA-CD40mAb scaffold has an anti-tumor effect by
locally releasing CD40mAb. Therefore, this immunological electro-
spun scaffold has very good potential to be developed as a powerful
tool for localized tumor treatment, and this is the first to be
reported in this area.
The recurrence of malignancies at the primary site is the major
cause of tumor-related deaths worldwide.1 In order to avoid the
recurrence of post-surgical tumors, chemotherapy, radiotherapy
or biotherapy is followed in the clinic to clear the remaining
asymptomatic tumor tissues completely. Among all kinds of
biotherapies, antibody-mediated immunotherapy displays enor-
mous potential in malignancy therapy because of its high specificity
and efficiency. It can drive immune cells and cytokines to eradicate
tumor cells2 or directly induce tumor cell death by recognizing
and interacting with tumor specific receptors.3 Compared with
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This paper reports an immunological electrospun scaffold for tumor cell
killing and healthy tissue regeneration. Herein, we have developed a
specific immunological tissue engineering scaffold using the agonistic
mouse anti-human CD40 antibody (CD40mAb) incorporated into a
poly(L-lactide) (PLLA) membrane through the dopamine (PDA) motif
(PLLA-PDA-CD40mAb). CD40mAb was successfully incorporated onto the
surface of the fibrous scaffold, which was proved by immunofluorescence
staining, and the PLLA-PDA-CD40mAb scaffold had an anti-tumor effect by
locally releasing CD40mAb. The developed CD40mAb-functionalized
electrospun PLLA-PDA fibrous scaffolds are multifunctional, which are
able to specifically eliminate CD40-expressed tumor cells by recognizing
CD40 receptors and regulating the expression levels of bcl-2 and bax. The
scaffolds promote human dendritic cell (DC) maturation to secrete IL-12
and IFN-g through CD40mAb cross-linking, thus activating specific
immune response, and annihilate tumor cells indirectly. The CD40mAb-
functionalized electrospun PLLA-PDA fibrous scaffolds are easy to
fabricate, biocompatible, and multifunctional in selectively inducing
tumor cell apoptosis, activating immune response and promoting
healthy tissue regeneration. Therefore, these immunological electrospun
fibers have very good potential to be developed as a powerful tool for
localized tumor treatment and can provide sustained drug release to
eliminate cancerous tissues, while restricting the drug release to avoid
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traditional chemotherapy or radiotherapy, antibody-based
biotherapy has high specificity, low side effects, predictability,
high patient compliance, and so on.4–7 However, when the anti-
body is delivered in vivo, it is difficult to maintain the therapeutic
concentration at the local site on account of the short antibody
half-life time and rapid antibody dissolution.8,9 Thus, enhancing
the accumulation of antibodies at the primary tumor site or the
tumor resection cavity is of great clinical importance.
In the recent decade, as a drug-eluting system, electrospun
nanofibrous scaffolds are widely used in tissue engineering and
regeneration medicine.10 Natural protein, synthetic polymer
or hybrid material based electrospun scaffolds, such as
collagen, gelatin, poly(L-lactide) (PLLA), poly(lactic-co-glycolic
acid) (PLGA) and poly(e-caprolactone) (PCL), are characterized
by high surface areas and three-dimensional (3D) micro–nano
structures.11 Furthermore, their unique features of good bio-
compatibility and biodegradability make them suitable for
potential application in the clinic. However, the bioinert
properties of these biomaterials significantly limit their utiliza-
tion. Thus, it is of great necessity to develop bio-inspired
electrospun scaffolds to replace, remodel or support damaged
tissues in regenerative medicine.12 Direct electrospinning or
coaxial electrospinning are common approaches to load drugs,
growth factors and proteins into the scaffolds.13 However, the
processing of protein integration and scaffold sterilization
easily inactivated the antibodies attached to electrospun
scaffolds.14,15 Recently, integrating proteins into scaffold
surfaces using specific motifs has become a new strategy for
bio-functioning electrospun scaffolds. The anti-CD31 antibody
was immobilized onto electrospun poly(e-caprolactone) scaffolds
with hydrophobins to promote the attachment and retention of
endothelial cells.16 The anti-CD34 antibody was integrated into a
polyurethane (PU) surface via amine-terminated polyethylene
glycol (PEG) to inhibit intimal hyperplasia in cardiovascular
applications.17 Herein, to maintain the activities of antibodies
on the fabricated fibers, it is of great necessity to conjugate the
antibodies using specific motifs.
The polydopamine (PDA) motif arouses interest in researchers
owing to its special characteristics.18 PDA is inspired from
Mytilus edulis foot protein 5 (Mefp-5) in the mussel, which is
rich in 3,4-dihydroxy-l-phenylalanine and lysine amino acids.
It can adhere to various substrates including metallic, inorganic,
and organic materials via spontaneous polymerization in mild
aqueous solution.19 PDA is reactive to nucleophilic functional
groups, such as amino and thiols via the catechol groups.
Thus, PDA is a good candidate for intermediating antibodies
to immobilize onto the surfaces of scaffolds.
CD40 is a type I membrane glycoprotein normally expressed
in B cells and dendritic cells (DCs).20 As immuomodulators,
CD40 and the CD40 ligand (CD40L) provide the costimulatory
signal in a broad spectrum of systemic immune and inflammatory
responses physiologically, including DC maturation, macrophage
cytokine secretion, T-cell-dependent cellular immunity and
humoral response.21–23 In biotherapy studies of antitumor
response, the anti-CD40 antibody (CD40mAb) combined with
the Toll-like receptor 3 (TLR3) ligand can restore DC-mediated
immunity to break up the tumor suppression induced by
morphine.24 CD40 signaling also primes DCs to enhance T cell
response against Lewis lung carcinoma in murines.25 In addition,
high expression of CD40 has been found in B cell neoplasms and
many kinds of solid malignancies, suggesting that CD40 signaling
is involved in the development of malignancies.26 Contact-
dependent CD40 cross-linking by agonistic CD40mAb can inhibit
proliferation of the myeloma cell line XG-227 and promotes the
apoptosis of the gastric cancer cell line AGS.28 Remarkably, CD40
signaling can enhance tumor cell sensitivity to chemotherapy and
radiotherapy.29
In the present study, we grafted agonist rat anti-human
CD40mAb onto the surfaces of PLLA electrospun fibrous
scaffolds through PDA motif-mediated crosslinking reaction
under mild aqueous conditions. The successful incorporation
of CD40mAb onto the PLLA-PDA scaffolds was demonstrated by
immunofluorescence staining. We also explored whether the
CD40mAb-modified scaffolds induced antitumor therapy by
directly triggering CD40-expressed tumor cell apoptosis and
indirectly through immunomodulation by stimulating DC
activation in vitro. In addition, we also investigated the effect
of the scaffolds’ structure on supporting the fibroblast prolifera-
tion (Scheme 1). At the end, we examined the anti-tumor efficacy
of CD40mAb released from the scaffolds in a murine model of
breast cancer.
PLLA membranes were prepared via electrospinning as
previously described.30 To prepare PLLA-PDA-mAb membranes,
the scaffolds were immersed into a PDA solution for 24 h for
PDA coating, and subsequently PLLA-PDA scaffolds were incorpo-
rated with agonist rat anti-human CD40mAb (PLLA-PDA-CD40mAb)
or rat immunoglobulin G (IgG) (PLLA-PDA-IgG) (Fig. 1a). As shown
in Fig. 1b, the fibrous morphologies of PLLA and PLLA con-
jugated with PDA (PLLA-PDA), PDA-IgG (PLLA-PDA-IgG), and
PDA-CD40mAb (PLLA-PDA-CD40mAb) had smooth surfaces
and showed no significant difference in monodispersed fibrous
diameters (0.94 0.21, 0.91 0.36, 0.91 0.17, and 0.93 0.23 mm,
respectively). Thus, PDA and antibody conjugation did not alter
the diameters of the scaffolds.
Next, we examined if PDA and CD40mAb were successfully
conjugated on the scaffold via X-ray photoelectron spectroscopy
(XPS) (Fig. 1c). Carbon (C1s, 284.5 eV) and oxygen (O1s, 531.0 eV)
peaks were observed in the PLLA electrospun fibrous scaffolds.
However, a clear nitrogen peak (N1s, 399.8 eV) appeared in the
electrospun fibrous scaffolds of PLLA-PDA, PLLA-PDA-IgG and
PLLA-PDA-CD40mAb, suggesting the amide bonds of PDA, IgG
and CD40mAb. Moreover, the areas of the N1s peaks increased
after grafting with IgG or CD40mAb, indicating that the antibodies
were successfully conjugated into the PLLA-PDA scaffolds.
One important parameter of the scaffolds for biomedical
applications is their mechanical properties. Surface modifica-
tion may change the physico-chemical properties of the fibrous
scaffolds and disabled their mechanical intensity in biomedical
applications. Thus, we tested the effect of antibody conjugation
on the mechanical properties of the scaffolds. Fig. 1d shows the
stress–strain curves of the PLLA scaffolds with or without PDA
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were 4.3  0.32 MPa, 4.2  0.12 MPa, 4.41  0.56 MPa and
4.51  0.33 MPa, with elongation at break rates of 47.17 
0.23%, 46.17  0.67%, 46.05  0.45% and 45.71  0.43% in
PLLA, PLLA-PDA, PLLA-PDA-IgG and PLLA-PDA-CD40mAb,
respectively. Therefore, the conjugation of PDA and the anti-
bodies did not affect the tensile strength. Taken together, the
results demonstrated that the coating approach via the PDA
motif to absorb the antibodies well retained the original
properties of the fibrous scaffolds.
The stability of the PLLA-PDA-CD40mA scaffolds was in vitro
investigated by immersing the PLLA-PDA-CD40mA scaffolds
into cell culture medium for 3 and 7 d at 37 1C and checking
the microstructures of the scaffolds by SEM. As shown in Fig. S1
(ESI†), the microstructures of the scaffolds were stable. More-
over, modification of conjugated PDA and the antibody may
also change the surface properties of the PLLA.14,15,17
To characterize the surface properties of the antibody-
modified fibers, the wettabilities of the electrospun scaffolds
were measured using a water contact angle (WCA) test. As
shown in Fig. 1e, the WCA of the PLLA scaffold was 122.07 
2.661, while the WCAs of the PLLA-PDA, PLLA-PDA-IgG and
PLLA-PDA-CD40mAb scaffolds were close to 01. It was indicative
that the PLLA electrospun fibrous scaffolds were hydrophobic,
but through PDA motif conjugation the surfaces of the fibrous
scaffolds fully changed into hydrophilic. After modification, the
color of the fibers turned from white to grey (Fig. S2, ESI†).
Thus, the successful immobilization of PDA and CD40mAb can
overcome the shortcomings of the extremely hydrophobic and
non-bioactive surfaces of the PLLA electrospun fibrous scaf-
folds and improve cell attachment and recruitment.
Next, we proved the successful incorporation of the anti-
bodies onto the surfaces of the PLLA scaffolds by immuno-
fluorescence staining with the antibodies conjugated with
fluorescein isothiocyanate (CD40mAb-FITC or IgG-FITC). As
expected, no green fluorescent signal was detected in the PLLA
and PLLA-PDA scaffolds, and neither in the PLLA scaffolds
mixed with purified CD40mAb without the FITC label (Fig. S3, ESI†).
In contrast, a fluorescent signal was observed in the PLLA-PDA
electrospun fibrous scaffolds conjugated with FITC-labeled
antibodies, demonstrating the successful immobilization of
IgG or CD40mAb onto the surfaces of the scaffolds.
In comparison to a flat membrane, an electrospun scaffold
has an advantage of an expanded surface because of its fibrous
structure. Accordingly, the density of CD40mAb attached to the
PLLA-PDA electrospun fibrous membrane is 1.49 0.11 mg (cm2)1,
as calculated using eqn (1).
Density mg cm2
 
¼M total massð Þ Mðresidual massÞ
Sðsuperficial areaÞ (1)
The grafting process of CD40mAb onto the PLLA-PDA scaffolds
could be divided into two stages (Fig. S4, ESI†). The grafting
speed of CD40mAb scaffolds was fast at the initial stage,
decreased significantly after 12 h and balanced after 24 h.
Therefore, we assumed that the grafting of CD40mAb onto
PLLA-PDA saturates after 24 h. In parallel, the release of
CD40mAb was also divided into two stages (Fig. S5, ESI†).
Scheme 1 The pipeline of CD40mAb-grafted electrospun fibrous scaffolds for anti-cancer therapy and tissue regeneration. (I) Released CD40mAb
directly induces tumor cell apoptosis. (II) Released CD40mAb activates dendritic cells (DCs) to initiate adaptive immune response to kill tumor cells
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Notably, we observed that most of CD40mAb are released to
reach a plateau within 48 h. Indeed, this state of the mild grafting
and consistent release of CD40mAb is important for the in vivo
successful delivery of the antibodies via the electrospun scaffolds.
CD40mAb-based therapy develops anti-tumor activity via
multiple mechanisms against a broad range of lymphoid
and solid malignancies.31 The human breast cancer cell line
MDA-MB-231 highly expresses CD40, which can be induced to
apoptosis by CD40 ligation with CD40L.32 With CD40 signalling
activation, MDA-MB-231 cells up-regulate the expression of the
pro-apoptotic Bax protein and down-regulate the expression of
the anti-apoptotic Bcl-2 protein; thus the increased Bax/Bcl-2
ratio determines the cell fate to apoptosis. The agonistic anti-
CD40 antibody has been verified to induce tumor cell apoptosis
and DC maturation in vitro.33 To further explore its biological
function, firstly, we evaluated the proliferative effect of the
PLLA-PDA-CD40mAb electrospun scaffolds on MDA-MB-231
cells. Different fibrous scaffolds were incubated in the cell
culture medium for 24 h and the mediums were then harvested
to culture MDA-MB-231 cells for 3 d. Cell proliferation was
determined using a CCK-8 kit. Cells cultured in the release
buffer from PLLA and PLLA-PDA-IgG show no statistically
significant difference in optical density (OD) compared with
the cells cultured in control medium (OD: 0.47  0.03 and
0.47  0.01 vs. 0.47  0.03) (Fig. 2a). PLLA displayed good
biological compatibility and PDA combined with isotype IgG
had no effect on the proliferation of tumor cells. In contrast,
the OD value of the MDA-MB-231 cells cultured with the release
buffer from PLLA-PDA-CD40mAb decreased significantly,
suggesting that the released CD40mAb in the buffer suppressed
the tumor cell proliferation. To investigate whether CD40mAb
could be released from the scaffolds constantly and the CD40mAb
activity could last for a long period of time, MDA-MB-231 cells
were cultured in the release buffer of PLLA-PDA-CD40mAb
collected at 12 h, 24 h, and 48 h for 3 d. As a result, no clear
time-dependent pattern was observed, which further proved that
the CD40mAb released from PLLA-PDA-CD40mAb maintained
its activity in the testing period (Fig. S6, ESI†).
Then, we seeded MDA-MB-231 cells onto the different
scaffolds directly for 24 h and performed live/dead staining
assay to evaluate the function of CD40mAb grafted onto the
PLLA scaffolds. With a fluorescence microscope, the images
displayed more dead cells (in red) on the PLLA-PDA-CD40mAb
scaffolds than the ones on the PLLA-PDA and PLLA-PDA-IgG
scaffolds (Fig. S7, ESI†). The SEM showed that, after 24 h, the
cells grown on the PLLA-PDA-CD40mAb scaffolds became
round, while the cells on the PLLA-PDA and PLLA-PDA-IgG
scaffolds had branches (Fig. S8, ESI†). The data confirm that
Fig. 1 Characterization of the PLLA-PDA-CD40mAb scaffold. (a) The cartoon of PLLA electrospun fibrous scaffolds with the antibody grafted through
PDA. (b) The morphologies of the different scaffolds under a SEM. (The insets present contact angles, which represent the polar properties of the
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the PLLA-PDA-CD40mAb scaffold can efficiently induce MDA-
MB-231 cell apoptosis and the mussel-inspired PDA coating
attributes to support the mild conjugation of CD40mAb with
the activity maintained for few days.
To identify the early apoptosis of MDA-MB-231 cells cultured
in the release buffer (24 h released, released concentration,
1 mg ml1), flow cytometry assay (FCA) was performed with an
apoptosis staining kit. The results showed that the apoptosis of
cells in the release buffers of PLLA-PDA and PLLA-PDA-IgG were
similar to that of the cells with control medium after
24 h culture. These data further confirm that the PLLA and
PLLA-PDA-IgG scaffolds have good compatibility. The number
of apoptotic cells was clearly higher in the release buffer of the
PLLA-PDA-CD40mAb scaffolds (Fig. 2c), which is consistent
with the results of the CCK-8 assay, indicating that the
PLLA-PDA-CD40mAb scaffolds can directly induce cancer cell
apoptosis.
Bcl-2 (B-cell lymphoma 2) and Bax are critical to develop-
ment, tissue homeostasis, and protection against pathogens.
Bcl-2 promotes cell survival by inhibiting adaptors needed for
the activation of the proteases (caspases) that dismantle the
cells.34 Bax, in contrast, accelerates apoptosis by activating
caspases. In our system, CD40mAb released from the fibrous
scaffolds interacted with CD40 antigens on MDA-MB-231 cells,
which is an initial step of CD40-mediated signal cascades and
activation of caspase-dependent cell death.31 qRT-PCR results
showed that the expression of Bax was statistically higher in the
cells cultured with released CD40mAb than the ones with
released IgG. Meanwhile, the expressions of Bcl-2 were similar
in all groups (Fig. 2b). Thus it further proves that through
released CD40mAb, the PLLA-PDA-CD40mAb scaffolds have a
capability to ‘‘kill’’ tumor cells.
It is well accepted that the CD40/CD40L signal constitutes a
critical co-stimulatory pathway to facilitate antigen presenting
cell (APC) activation and cytotoxic T lymphocyte-mediated
immunity against cancer.35 Next we further explored its
co-stimulatory effect on the maturation of DCs. As an important
source of antigen-presenting cells (APCs), immature DCs have a
high capability of sampling the surrounding environment
through endocytosis. This process promotes the maturation
of DCs, which greatly enhances their ability to initiate adaptive
immune response and activate antigen responsive T cells to kill
target cells by perforins and granzymes.36,37 Moreover, matured
DCs themselves express and stimulate other cells to express
cytokines, such as IL-12 and IFN-g, to activate nonspecific
immune response to eliminate tumor cells.38,39 Thus, local
application of CD40mAb via PLLA elctrospun scaffolds could
play an important role in cancer therapy in the region of
interest. In this study, we collected the released buffer to
stimulate DC maturation in vitro. Adherent peripheral blood
mononuclear cells (PBMCs) from healthy donors were incubated
with free CD40mAb (1 mg ml1) or the released buffers from the
different PLLA electrospun membranes. As positive control,
PBMCs were induced for mature DCs with a GM-CSF and IL-4
Fig. 2 The anti-proliferation effect of CD40mAb released from PLLA-PDA-CD40mAb scaffolds for 24 h towards MDA-MB-231 cells. (a) Cell viability of
MDA-MB-231. (b) The relative gene expressions of Bax and Bcl-2 of MDA-MB-231 cells (data are represented as fold changes normalized by cells
cultured in cell medium). (c) Flow cytometry assay (FCA) for MDA-MB-231 cell apoptosis. Control: cells seeding onto the plate (compared with the PLLA
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cocktail. After 10 d induction of DCs, all the suspended cells
were photographed and harvested to perform FCA. As previous
research reported,33 PBMCs with cytokines (GM-CSF and IL-4
treated) were expended and formed a dendritic shape (Fig. S9,
ESI†), and had a tendency to cluster together (Fig. 3a). The
expression of mature DC markers, CD11c and HLA-DR, of these
cells increased distinctly (Fig. 3b). However, the cells in the
released buffers from PLLA-PDA and PLLA-PDA-IgG retained the
original shape, small and scattered, as the untreated control
group. Remarkably, the cells cultured with both PLLA-PDA-
CD40mAb released buffer and free CD40mAb displayed similar
morphologies to that of mature DCs induced by the GM-CSF and
IL-4 cocktail (Fig. 3a and b)40 The expression of HLA-DR in the
cells with the released buffer from the PLLA-PDA-CD40mAb
scaffold was similar to that of purified CD40mAb; however,
it was much higher than those with the released buffers of
Fig. 3 CD40mAb released from the PLLA-PDA-CD40mAb scaffold activates DCs from PBMCs. (a) The morphology of DCs and (b) the expressions of
CD11c and HLA-DR. Control: cells seeded into culture medium without cytokines and antibodies. MFI: median fluorescence intensity. The proliferation
effect of PLLA-PDA-CD40mAb on MC3T3-E1 cells. (c) SEM images of MC3T3-E1 cells seeded onto the electrospun PLLA-PDA, PLLA-PDA-IgG and
PLLA-PDA-CD40mAb scaffolds for 3 d. (d) Live/dead staining of MC3T3-E1 cells seeded onto the electrospun PLLA-PDA, PLLA-PDA-IgG and PLLA-PDA-
CD40mAb scaffolds for 3 d. (e) CCK-8 assay of MC3T3-E1 cells cultured in the released buffer (24 h) for 1, 3, and 5 d. (f) CCK-8 assay of MC3T3-E1 cells
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PLLA-PDA and PLLA-PDA-IgG (Table S2, ESI†). Therefore, our
results showed that the PLLA-PDA-CD40mAb scaffolds had the
capability to promote the maturation of DCs by providing CD40
signaling. We speculate that matured DCs can induce the
expression of cellular signals and kill tumor cells by T cell-
mediated immune response. Since the activation of DCs is an
important process for antitumor immunity, we also expect that
the PLLA-PDA-CD40mAb platform promotes DC maturation to
secrete IL-12 and IFN-g through CD40 cross-linking, which has
been a well-demonstrated pathway to annihilate cancer cells
in vivo.40
PLLA scaffolds have been widely applied to regenerate or
remodel tissue in injured regions.41 They provide an ECM-like
three-dimensional (3D) microenvironment to support cell
adhesion physically and proliferation.42–44 We hypothesise that
in addition to cancer therapy the electrospun scaffolds can also
provide physical support for the regeneration of inspired tissue.
In this work, we seeded mouse preosteoblast MC3T3-E1 cells
onto the fibrous scaffolds to assess the tissue regeneration
capability of the PLLA scaffolds. The cellular morphology and
cell–scaffold interaction were imaged with SEM. The pictures in
Fig. 3c show that the cells grown on the different scaffolds had
the same flat structure after 3 d and the cells connected with
each other. Live/dead staining assay showed that the cells seeded
onto the PLLA-PDA, PLLA-PDA-IgG and PLLA-PDA-CD40mAb
scaffolds grew well with few dead cells (shown in red) detected
(Fig. 3d). The live cells in green on the scaffolds displayed good
activity with polygon and fusiformis shapes, connected with each
other and well-spread. Thus, the CD40mAb conjugation and
release process didn’t affect the properties of the scaffolds on
inducing tissue regeneration.
Since the commercial CD40mAb also recognizes mouse-
original CD40 molecules, we harvested the released buffers
(24 h) of the different scaffolds and studied the growth effect
of the released CD40mAb on MC3T3-E1 cells for 1, 3, and 5 d
incubations. As a result, there was no significant difference
between the different groups at the same time points (Fig. 3e).
As parallel experiments, we also collected released buffers of
the different scaffolds at 12 h, 24 h, and 48 h and cultured
MC3T3-E1 cells for another 3 d without scaffolds. The OD
values of the cells between the different groups showed no
statistical difference (Fig. 3f). The results indicated that the
CD40mAb conjugation and release process influenced neither
the properties of the scaffolds nor the growth of MC3T3-E1
cells. MC3T3-E1 cells didn’t respond to CD40mAb under such
situations because of the lack of CD40 expression on the cell
surface. Thus, we proposed that the PLLA-PDA-CD40mAb
scaffold was multifunctional, which not only specifically ‘‘killed’’
tumor cells that express CD40, but also provided physical support
to promote cell proliferation in vitro.
Inspired by the anti-tumor efficiency and as a solid scaffold
for cell growth of PLLA-PDA-CD40mAb scaffolds in vitro,
we further examined the cancer therapeutic effect of the PLLA-
PDA-CD40mAb scaffolds on the induction of tumor cell apoptosis
in vivo. Severe combined immunodeficiency (SCID) mice are
characterized by lack of T cells, B cells and detectable antibodies.
Though they can’t induce specific immune response in vivo, they
are a well-established model for implanting humanized tumor
cells. In our study, human MDA-MB-231 breast cancer cells
bearing tumours were developed in the axillary regions of
severe SCID mice. After tumor masses were formed, parts of
tumor mass were removed by surgery and the residual tumor
masses (3 3 3 mm3) were left in situ. The PLLA, PLLA-PDA-IgG
and PLLA-PDA-CD40mAb scaffolds were used to cover the cross-
section. We also set one group as the positive control by direct
injection of CD40mAb (2 mg) around the tumor mass. All the mice
were euthanized and the tumours were collected 14 d after the
treatment. As shown in Fig. 4a, the tumor mass without removal
and treatment grew in an uncontrollable manner. As we expected,
the tumor volumes in the mice treated with free CD40mAb buffer
or the PLLA-PDA-CD40mAb scaffold were obviously smaller than
the ones in the other two groups covered with the PLLA and
PLLA-PDA-IgG scaffolds (Fig. 4b). The mean size of the tumor
masses in the PLLA-PDA-CD40mAb group was the smallest among
all the groups, further confirming that the PLLA-PDA-CD40mAb
membranes could effectively inhibit tumor growth.
We further examined the therapeutic efficacy of PLLA-PDA-
CD40mAb scaffolds by the typical morphological assay (Fig. 4c).
Hexatoxylin and eosin (H&E) staining images revealed that
MDA-MB-231 cells were found in all groups. In the groups with
the different PLLA scaffolds, non-degraded fibers were also
observed in the tumor mass. Most MDA-MB-231 cells were dead
in either the free CD40mAb or PLLA loaded CD40mAb-treated
groups. Since Ki67 proliferation is a prognostic and predictive index
in breast cancer,45 we performed Ki67 immunohistochemical
staining. The Ki67 expression of MDA-MB-231 cells in the
PLLA-PDA-CD40mAb group was significantly less than the ones
of the other four groups. In contrast, terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) staining assay indi-
cated that the MDA-MB-231 cells from the PLLA-PDA-CD40mAb
group were largely apoptotic; however, they were alive in the
other groups. Quantitative analysis (Fig. 4d) further demon-
strated that there were significant differences between the
PLLA-PDA-CD40mAb group and the other groups. All of the
results, from another perspective, are state-of-the-art proof
that the PLLA-PDA-CD40mAb scaffolds can significantly inhibit
the tumor growth by suppressing the cell proliferation and
inducing the apoptosis of tumor cells in vivo. We speculate that
CD40mAb attached to the scaffold activates the CD40 signaling
of the tumor cell line MDA-MB-231 and ‘‘kill’’ the tumor cells
successfully in vivo. Meanwhile, since the PLLA scaffolds absorb
CD40mAb through the PDA motif, the system could avoid the
side effects caused by CD40mAb burst and rapid diffusion
when the free CD40mAb is applied in vivo.
In conclusion, CD40mAb is successfully conjugated to PLLA
mediated by PDA and the activity of the antibody is well
retained. In addition, the PDA and CD40mAb conjugation does
not influence the mechanical properties, but alters the PLLA
surface from hydrophobic to hydrophilic to facilitate the cell
attachment. The CD40mAb-functionalized electrospun PLLA-PDA
fibrous scaffolds are multifunctional, which are able to specifically
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molecules and inducing cell apoptosis via a Bcl-2/Bax-dependent
pathway. In addition, the scaffolds promote DC maturation via
CD40mAb cross-linking in vitro, though its antitumor function
needs to be further explored. More interestingly, the scaffolds
provide a 3D platform to support fibroblast proliferation,
suggesting that the system is favourable for inducing healthy tissue
regeneration in vivo. The CD40mAb-functionalized electrospun
PLLA-PDA fibrous scaffolds are easy to fabricate, biocompatible,
and functional in selectively inducing tumor cell apoptosis via
multiple mechanisms, and promoting tissue regeneration.
As a result, they could be promising antibody-delivery systems
for cancer therapy, especially for local administration to
promote tumor cell death and avoid the recurrence of tumors
post-surgically.
Fig. 4 In vivo anticancer efficiency of PLLA-PDA-CD40mAb membranes. (a) The representative photographs of the tumors after various treatments and
quantification of tumor masses in the different groups indicated. (b) The volumes of tumor masses. (c) H&E stained images, immunohistochemical
analysis and TUNEL apoptosis assay (green: apoptotic cells; blue: nuclei) of tumor tissues after membrane-treated therapy. (d) Quantification of the
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Experimental
Details on the experimental procedures are provided in the ESI.†
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